Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
Patrick is the managing editor of PharmaBoardroom
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Sanofi’s inflammation drug Dupixent® is driving a substantial percentage of the firm’s sales in 2020, reaching USD 1.92 billion in the first half of the year, with a reported growth…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on…
Saudi Arabia is seeing an increased demand for more innovative medical devices and a greater awareness of the myriad ways that medical technology can be used for screening illnesses such…
The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a Covid-19 drug, in South Africa this month. The company’s priority is ensuring access…
In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response…
Swiss giant Roche tops Pharmaceutical Executive’s 2020 list of the world’s biggest pharma companies, up from second place in 2019 and third in 2018. Though its best-selling drugs are soon…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
A new report by Novartis looks at how leading talent in the technology industry is increasingly looking to bring their skillsets into the healthcare and life sciences industries against the…
See our Cookie Privacy Policy Here
